Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

Recruiting

Phase 3

CagrilintideWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

Sponsor:

Novo Nordisk A/S

Code:

NCT07220759

Conditions

Overweight

Obesity

Type 2 Diabetes

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Cagrilintide

Placebo (matched to Cagrilintide)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-22. This information was provided to ClinicalTrials.gov by Novo Nordisk A/S on 2025-12-12.